Professor Michael Jung has been selected to receive the 13th AACR Award for Outstanding Achievement in Chemistry in Cancer Research.
The prestigious award is presented to researchers for outstanding, novel, and significant chemistry research, which has led to important contributions to the fields of basic cancer research, translational cancer research, or the treatment of patients with cancer.
Jung will be honored at the Annual Awards Recognition Dinner on Saturday, March 30 at the AACR Annual Meeting 2019, to be held March 29-April 3 in Atlanta. He will present his award lecture titled “Drug Discovery in Academia: Cancer Research” on Tuesday, April 2, at 3 p.m., Room B304, Georgia World Congress Center.
The AACR and its Chemistry in Cancer Research Working Group established the Outstanding Achievement in Chemistry in Cancer Research Award in 2007 to recognize the importance of chemistry in advancing cancer research.
A distinguished professor of chemistry and biochemistry and Associate Dean for Entrepreneurship and Innovation at UCLA, Jung is a leader in the field of synthetic organic and medicinal chemistry. His breakthrough anti-prostate cancer drugs – Xtandi and Erleada – have extended the lives of men with late-stage prostate cancer. In 2018, Jung received the Amgen Early Innovator Award for his research on Alzheimer’s disease.
In 2017, Jung and his wife Alice endowed The Michael & Alice Jung Chair in Medicinal Chemistry and Drug Discovery to enable UCLA to hire a faculty member who will conduct drug discovery research with the goal of producing new, life-saving drugs well into the future.
To learn more about Jung’s research, visit his group’s website.
Penny Jennings/UCLA Department of Chemistry & Biochemistry, penny@chem.ucla.edu.
